Posted 2/28/2024, 4:18:00 PM
Viking Therapeutics Stock Soars 145% on Positive Weight Loss Drug Data, Analysts Bullish on VK2735 Potential
- Viking Therapeutics' stock rose 145% this week after positive trial data for its weight-loss drug VK2735
- Analysts are very bullish on the data and believe VK2735 could achieve over 20% weight loss in longer trials
- Analysts raised their price targets significantly, with targets now between $115-$120
- Analysts say Viking is now an attractive acquisition target, with its NASH program adding value
- Next steps are meeting with the FDA and likely a Phase 2b trial that could test once-monthly dosing